Sarepta Therapeutics | SRPT - Trade Creditors


Sarepta Therapeutics reported $70.38M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Capricor Therapeutics 3.93M 2.27M Mar/2026
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
Eli Lilly USD 5.03B 350M Mar/2026
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Moderna USD 161M 156M Mar/2026
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novavax USD 16.1M 8.48M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.71B 219M Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Tectonic Therapeutic USD 2.55M 1.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026